Allergic Bronchopulmonary Aspergillosis Clinical Trial
Official title:
A Prospective, Two-center, Clinical Study to Optimize the Treatment for Allergic Bronchopulmonary Aspergillosis (ABPA)
This study is being done to evaluate the efficacy of treatment using oral glucocorticoid, anti-fungal agent, anti-IgE mAb for patient with ABPA.
This is a study randomly treating ABPA patients with either anti-fungal agent plus OCS or anti-IgE mAb (omalizumab) plus OCS. OCS is the basic treatment for ABPA by suppressing allergy and inflammation. Prednisone tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to for a total usage of 6 months. Reduction may failed if disease exacerbate. Anti-fungal agent (mainly itraconazole) could reduce the load of fungus but its application is still controversial. The investigators use itraconazole 200mg bid for 8 months and 100mg bid for another 8 months. Omalizumab was given 600mg q4w for at least 6 months. The investigators use Anti-fungal agent and Omalizumab as a supplement to OCS to evaluate the better treatment plan for ABPA patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01222273 -
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
|
N/A | |
| Completed |
NCT04442269 -
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
|
Phase 2 | |
| Terminated |
NCT00787917 -
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
|
Phase 4 | |
| Completed |
NCT02273661 -
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
|
Phase 2 | |
| Completed |
NCT02440009 -
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Completed |
NCT01857479 -
A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06244979 -
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
|
Phase 2 | |
| Completed |
NCT00585364 -
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
|
N/A | |
| Completed |
NCT01621321 -
Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05444946 -
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
|
N/A | |
| Terminated |
NCT03960606 -
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
|
Phase 2 | |
| Active, not recruiting |
NCT04227483 -
Deflazacort vs. Prednisolone in Acute-stage ABPA
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT05903612 -
Allergic Bronchopulmonary Aspergillosis Prescreening Study
|
||
| Completed |
NCT04229303 -
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
|
Phase 1 | |
| Completed |
NCT04476758 -
Immune Profiles in CF Fungal Infection
|
||
| Withdrawn |
NCT04108962 -
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
|
Phase 4 | |
| Recruiting |
NCT06174922 -
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
|
Phase 3 | |
| Completed |
NCT01321827 -
Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00974766 -
Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Completed |
NCT03059992 -
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
|
Phase 3 |